Francisco Javier Ramos
Research Subjects
Francisco Javier Ramos has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Josep Tabernero
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
24 shared publications - Teresa Macarulla
Hospital Clínic Barcelona, Translational Oncology in Upper Gastrointestinal Cancer Group, IDIBAPS, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
18 shared publications - Elena Élez
Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
6 shared publications Jaume Capdevila
6 shared publications- Erika Martinelli
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy
4 shared publications - Cristina Saura
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
3 shared publications
Latest Publications
- 17 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2174-2182
Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal adenocarcinoma undergoing systemic treatment
Background Dysregulated lipid metabolism is common in patients with gastrointestinal (GI) cancer. This study investigated the ability of plasma lipidome variation during systemic treatment to classify GI cancer patients according to tumor response. Methods Non-targeted plasma lipidomics with LC-qTOF mass spectrometry was conducted in patients with advanced GI adenocarcinomas before and after three months of systemic standard-of-care antitumor treatment. Bayesian ANOVA with repeated measures and an uninformative prior was used to screen for analytes whose before-and-after variation could be associated with tumor response. Suitable candidates with a Bayes Factor (BF) > 7 for the interaction were used to train a KNN model to classify patients as responders (PR + CR) vs. non-responders (PD + SD) according to RECIST 1.1 criteria. Results Thirty patients were included (18 colorectal, 6 gastric, 6 biliopancreatic). The cohort included 10 responders (all partial responses, 33%) and 20 non-responders (14 stable disease, 6 progressive disease). Plasma lipidomics identified 262 analytes on 10 lipid species: phosphatidylcholines (PCs), non-polar and polar lyso-PCs, sphingomyelins, lysophosphatidylethanolamines, cholesterol esters, acylglycerides, fatty acids, hormones, and bile acids. An increase in abundance after treatment of five PCs (PC32:2, PC33:2, PC36:2, PC36:5, PC38:5) was associated with tumor response (BF > 7 for interaction). After excluding collinear PCs (retaining PC32:2, PC33:2, PC36:2), a KNN model (optimized: k = 7, Manhattan distance, inverse weighting, LOOCV) achieved consistent performance over 20 runs (mean ± SD): AUC 0.86 ± 0.23; Precision 0.76 ± 0.17; Recall 0.81 ± 0.15; F1 score 0.80 ± 0.13; MCC 0.66 ± 0.23. None of the other nine lipid classes contributed more than one analyte with a BF > 7 for the interaction with tumor response. Conclusions Tumor response is associated with variations in plasma lipidome in patients with advanced GI cancer. The plasma abundance of PCs increased after treatment in responder patients, suggesting that further investigation may be warranted on PCs as a potential biomarker.
- 17 December 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2174-2182
Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal adenocarcinoma undergoing systemic treatment
Background Dysregulated lipid metabolism is common in patients with gastrointestinal (GI) cancer. This study investigated the ability of plasma lipidome variation during systemic treatment to classify GI cancer patients according to tumor response. Methods Non-targeted plasma lipidomics with LC-qTOF mass spectrometry was conducted in patients with advanced GI adenocarcinomas before and after three months of systemic standard-of-care antitumor treatment. Bayesian ANOVA with repeated measures and an uninformative prior was used to screen for analytes whose before-and-after variation could be associated with tumor response. Suitable candidates with a Bayes Factor (BF) > 7 for the interaction were used to train a KNN model to classify patients as responders (PR + CR) vs. non-responders (PD + SD) according to RECIST 1.1 criteria. Results Thirty patients were included (18 colorectal, 6 gastric, 6 biliopancreatic). The cohort included 10 responders (all partial responses, 33%) and 20 non-responders (14 stable disease, 6 progressive disease). Plasma lipidomics identified 262 analytes on 10 lipid species: phosphatidylcholines (PCs), non-polar and polar lyso-PCs, sphingomyelins, lysophosphatidylethanolamines, cholesterol esters, acylglycerides, fatty acids, hormones, and bile acids. An increase in abundance after treatment of five PCs (PC32:2, PC33:2, PC36:2, PC36:5, PC38:5) was associated with tumor response (BF > 7 for interaction). After excluding collinear PCs (retaining PC32:2, PC33:2, PC36:2), a KNN model (optimized: k = 7, Manhattan distance, inverse weighting, LOOCV) achieved consistent performance over 20 runs (mean ± SD): AUC 0.86 ± 0.23; Precision 0.76 ± 0.17; Recall 0.81 ± 0.15; F1 score 0.80 ± 0.13; MCC 0.66 ± 0.23. None of the other nine lipid classes contributed more than one analyte with a BF > 7 for the interaction with tumor response. Conclusions Tumor response is associated with variations in plasma lipidome in patients with advanced GI cancer. The plasma abundance of PCs increased after treatment in responder patients, suggesting that further investigation may be warranted on PCs as a potential biomarker.
- 11 November 2017
- Published by Springer Nature in Targeted Oncology
- Vol. 13 (1) , 69-78
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional oesophageal cancer patients, despite a non-negligible failure rate.
- 11 November 2017
- Published by Springer Nature in Targeted Oncology
- Vol. 13 (1) , 69-78
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional oesophageal cancer patients, despite a non-negligible failure rate.
- 14 November 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (22) , 6296-6304
Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design: Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled. Dose levels of 0.6 to 4.5 mg/m2 were explored. Results: Forty patients [24M/16F, median age 61 years (45–79)] were enrolled. At 4.5 mg/m2, dose-limiting toxicity (DLT) consisted of grade 3 diarrhea, nausea, and vomiting and grade 4 diarrhea, respectively, in two patients. At 4.0 mg/m2, DLT (grade 3 nausea, vomiting, and abdominal cramps) was observed in one patient. Frequently occurring side effects were mainly gastrointestinal. After drug discontinuation at 4.0 mg/m2, one patient experienced reversible grade 4 blurred vision. The maximum tolerated dose (MTD) is 4.0 mg/m2. No complete or partial responses during treatment were observed; one patient at 4.0 mg/m2 had a confirmed partial response after drug discontinuation. Pharmacokinetic analysis revealed a large volume of distribution, high systemic clearance, and a plasma elimination half-life of 5.3 to 15.1 hours. Overall drug exposure increased in a dose-dependent manner. At the MTD, mRNA levels of selected target genes monitored in peripheral blood mononuclear cells showed a reversible 15- to 25-fold decrease, whereas unspliced pre-mRNA levels of DNAJB1 and EIF4A1 showed a reversible 10- to 25-fold increase. Conclusion: The MTD for E7107 using this schedule is 4.0 mg/m2. Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107. Clin Cancer Res; 19(22); 6296–304. ©2013 AACR.
- 14 November 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (22) , 6296-6304
Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5-minute bolus infusions on days 1, 8, and 15 in a 28-day schedule. Experimental Design: Patients with solid tumors refractory to standard therapies or with no standard treatment available were enrolled. Dose levels of 0.6 to 4.5 mg/m2 were explored. Results: Forty patients [24M/16F, median age 61 years (45–79)] were enrolled. At 4.5 mg/m2, dose-limiting toxicity (DLT) consisted of grade 3 diarrhea, nausea, and vomiting and grade 4 diarrhea, respectively, in two patients. At 4.0 mg/m2, DLT (grade 3 nausea, vomiting, and abdominal cramps) was observed in one patient. Frequently occurring side effects were mainly gastrointestinal. After drug discontinuation at 4.0 mg/m2, one patient experienced reversible grade 4 blurred vision. The maximum tolerated dose (MTD) is 4.0 mg/m2. No complete or partial responses during treatment were observed; one patient at 4.0 mg/m2 had a confirmed partial response after drug discontinuation. Pharmacokinetic analysis revealed a large volume of distribution, high systemic clearance, and a plasma elimination half-life of 5.3 to 15.1 hours. Overall drug exposure increased in a dose-dependent manner. At the MTD, mRNA levels of selected target genes monitored in peripheral blood mononuclear cells showed a reversible 15- to 25-fold decrease, whereas unspliced pre-mRNA levels of DNAJB1 and EIF4A1 showed a reversible 10- to 25-fold increase. Conclusion: The MTD for E7107 using this schedule is 4.0 mg/m2. Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107. Clin Cancer Res; 19(22); 6296–304. ©2013 AACR.
- Open Access
- 13 February 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1567-1573
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study evaluated the efficacy and safety of single agent PEP02 compared with irinotecan or docetaxel in the second-line treatment of advanced oesophago-gastric (OG) cancer. Patients with locally advanced/metastatic disease who had failed one prior chemotherapy regimen were randomly assigned to PEP02 120 mg/m2, irinotecan 300 mg/m2 or docetaxel (Taxotere) 75 mg/m2 every 3 weeks. The primary end point was objective response rate (ORR). Simon's two-stage design was used and the ORR of interest was 20% (α = 0.05, type II error β = 0.10, null hypothesis of ORR was 5%). Forty-four patients per arm received treatment, and 124 were assessable for response. The ORR statistical threshold for the first stage was reached in all arms. In the intent-to-treat (ITT) population, ORRs were 13.6% (6/44), 6.8% (3/44) and 15.9% (7/44) in the PEP02, irinotecan and docetaxel arms, respectively. The median progression-free survival (PFS) and overall survival were similar between the trial arms. Commonest grade 3–4 adverse event reported was diarrhoea in the PEP02 and irinotecan groups (27.3% versus 18.2%). The ORR associated with PEP02 was comparable with docetaxel and numerically greater than that of irinotecan. PEP02 warrants further evaluation in the advanced gastric cancer setting.
- 13 February 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (6) , 1567-1573
Open AccessA randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study evaluated the efficacy and safety of single agent PEP02 compared with irinotecan or docetaxel in the second-line treatment of advanced oesophago-gastric (OG) cancer. Patients with locally advanced/metastatic disease who had failed one prior chemotherapy regimen were randomly assigned to PEP02 120 mg/m2, irinotecan 300 mg/m2 or docetaxel (Taxotere) 75 mg/m2 every 3 weeks. The primary end point was objective response rate (ORR). Simon's two-stage design was used and the ORR of interest was 20% (α = 0.05, type II error β = 0.10, null hypothesis of ORR was 5%). Forty-four patients per arm received treatment, and 124 were assessable for response. The ORR statistical threshold for the first stage was reached in all arms. In the intent-to-treat (ITT) population, ORRs were 13.6% (6/44), 6.8% (3/44) and 15.9% (7/44) in the PEP02, irinotecan and docetaxel arms, respectively. The median progression-free survival (PFS) and overall survival were similar between the trial arms. Commonest grade 3–4 adverse event reported was diarrhoea in the PEP02 and irinotecan groups (27.3% versus 18.2%). The ORR associated with PEP02 was comparable with docetaxel and numerically greater than that of irinotecan. PEP02 warrants further evaluation in the advanced gastric cancer setting.
- Open Access
- 29 March 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23 (1) , 119-127
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
Background: This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). Patients and methods: In this multicentre, phase I, open-label, dose-finding trial, FOLFIRI was administered every 2 weeks. Two sunitinib regimens were explored: Schedule 4/2 (4 weeks on, 2 weeks off; 37.5 and 50 mg/day) and continuous daily dosing (CDD; 37.5 and 25 mg/day). Dose-limiting toxic toxicities (DLTs) were evaluated during weeks 1–6. Efficacy was a secondary objective. Results: Thirty-seven patients were enrolled. The 37.5 mg/day Schedule 4/2 cohort had zero of six DLTs, was expanded by 15 patients and declared the MTD. The MTD was exceeded at all other sunitinib doses and schedules; DLTs included febrile neutropenia (n = 1), grade 4 neutropenia (n = 4) and grade 3 deep vein thrombosis with grade 4 neutropenia (n = 1). At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5–79.7). Conclusions: The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2. CDD of sunitinib at 37.5 or 25 mg/day plus FOLFIRI was not feasible.
- 29 March 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23 (1) , 119-127
Open AccessA phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
Background: This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). Patients and methods: In this multicentre, phase I, open-label, dose-finding trial, FOLFIRI was administered every 2 weeks. Two sunitinib regimens were explored: Schedule 4/2 (4 weeks on, 2 weeks off; 37.5 and 50 mg/day) and continuous daily dosing (CDD; 37.5 and 25 mg/day). Dose-limiting toxic toxicities (DLTs) were evaluated during weeks 1–6. Efficacy was a secondary objective. Results: Thirty-seven patients were enrolled. The 37.5 mg/day Schedule 4/2 cohort had zero of six DLTs, was expanded by 15 patients and declared the MTD. The MTD was exceeded at all other sunitinib doses and schedules; DLTs included febrile neutropenia (n = 1), grade 4 neutropenia (n = 4) and grade 3 deep vein thrombosis with grade 4 neutropenia (n = 1). At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5–79.7). Conclusions: The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2. CDD of sunitinib at 37.5 or 25 mg/day plus FOLFIRI was not feasible.
- 1 March 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (7) , 1181-1189
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
Purpose: This study assessed biomarkers for cetuximab efficacy in tissue samples collected during a phase I dose-escalation study exploring every second week administration of cetuximab as first-line therapy in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Sixty-two patients received cetuximab monotherapy for 6 weeks, followed by cetuximab plus infusional fluorouracil, leucovorin, and irinotecan until disease progression. Patients in the control arm received cetuximab as a 400 mg/m2 initial dose then 250 mg/m2 per week; patients in the dose-escalation arms received 400 to 700 mg/m2 every second week. Tumor and skin biopsies were taken for immunohistochemical and microarray expression analyses (tumor only) at baseline and week 4. Plasma was collected for proteomic analysis at baseline and week 4. KRAS tumor mutation status was assessed. Results: In subsets of paired skin samples from 35 patients, cetuximab treatment was associated with substantial downregulation of phospho(p)-EGFR, p-MAPK and proliferation and substantial upregulation of p27Kip1 and p-STAT3 levels. No marked difference in these effects was noted for different schedules of administration and dose levels. In the cetuximab monotherapy phase, responses were seen only in patients whose tumors were wild-type for KRAS (eight of 29 v zero of 19 for KRAS mutant tumors; P = .015). Progression-free survival was longer for patients with KRAS wild-type compared with KRAS mutant tumors (log-rank P = .048). Genomics/proteomics analyses (42 and 45 patients, respectively) identified candidate biomarkers associated with response. Conclusion: Biomarker analysis supported the functional equivalence of weekly and every second week administration of cetuximab and provided further confirmation that patients with KRAS wild-type mCRC were those most likely to benefit from cetuximab treatment.
- 1 March 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (7) , 1181-1189
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
Purpose: This study assessed biomarkers for cetuximab efficacy in tissue samples collected during a phase I dose-escalation study exploring every second week administration of cetuximab as first-line therapy in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Sixty-two patients received cetuximab monotherapy for 6 weeks, followed by cetuximab plus infusional fluorouracil, leucovorin, and irinotecan until disease progression. Patients in the control arm received cetuximab as a 400 mg/m2 initial dose then 250 mg/m2 per week; patients in the dose-escalation arms received 400 to 700 mg/m2 every second week. Tumor and skin biopsies were taken for immunohistochemical and microarray expression analyses (tumor only) at baseline and week 4. Plasma was collected for proteomic analysis at baseline and week 4. KRAS tumor mutation status was assessed. Results: In subsets of paired skin samples from 35 patients, cetuximab treatment was associated with substantial downregulation of phospho(p)-EGFR, p-MAPK and proliferation and substantial upregulation of p27Kip1 and p-STAT3 levels. No marked difference in these effects was noted for different schedules of administration and dose levels. In the cetuximab monotherapy phase, responses were seen only in patients whose tumors were wild-type for KRAS (eight of 29 v zero of 19 for KRAS mutant tumors; P = .015). Progression-free survival was longer for patients with KRAS wild-type compared with KRAS mutant tumors (log-rank P = .048). Genomics/proteomics analyses (42 and 45 patients, respectively) identified candidate biomarkers associated with response. Conclusion: Biomarker analysis supported the functional equivalence of weekly and every second week administration of cetuximab and provided further confirmation that patients with KRAS wild-type mCRC were those most likely to benefit from cetuximab treatment.
- Open Access
- 25 November 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (7) , 1537-1545
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Background: This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods: The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m2 initial dose, then 250 mg/m2/week and in the dose-escalation group, at 400–700 mg/m2, every second week. Results: Sixty-two patients were included in the study. The MTD of cetuximab administered on an every-second-week schedule was not reached. The safety profiles were similar across all groups. Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively. Trough levels for the 500, 600 mg/m2 and standard weekly regimens were comparable. Conclusion: Cetuximab can be safely administered once every second week at doses between 400 and 700 mg/m2, with 500 mg/m2 being the most convenient and feasible dose for future studies.
- 25 November 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (7) , 1537-1545
Open AccessCetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Background: This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods: The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m2 initial dose, then 250 mg/m2/week and in the dose-escalation group, at 400–700 mg/m2, every second week. Results: Sixty-two patients were included in the study. The MTD of cetuximab administered on an every-second-week schedule was not reached. The safety profiles were similar across all groups. Response rates in the cetuximab monotherapy and combination therapy phases were 15% and 42%, respectively. Trough levels for the 500, 600 mg/m2 and standard weekly regimens were comparable. Conclusion: Cetuximab can be safely administered once every second week at doses between 400 and 700 mg/m2, with 500 mg/m2 being the most convenient and feasible dose for future studies.
- 30 September 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45, 79-88
New approaches and targets in advanced colorectal cancer
- 30 September 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45, 79-88
New approaches and targets in advanced colorectal cancer
- 31 July 2009
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 71 (1) , 53-61
The role of salvage treatment in advanced colorectal cancer
- 31 July 2009
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 71 (1) , 53-61
The role of salvage treatment in advanced colorectal cancer